Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,260,185
  • Shares Outstanding, K 101,856
  • Annual Sales, $ 139,740 K
  • Annual Income, $ -79,990 K
  • EBIT $ -384 M
  • EBITDA $ -377 M
  • 60-Month Beta 2.12
  • Price/Sales 17.22
  • Price/Cash Flow N/A
  • Price/Book 1.94

Options Overview Details

View History
  • Implied Volatility 77.85% (+8.32%)
  • Historical Volatility 64.75%
  • IV Percentile 40%
  • IV Rank 36.26%
  • IV High 122.94% on 02/11/26
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 18) 3.49 (15.68%)
  • Put/Call Vol Ratio 1.03
  • Today's Volume 77
  • Volume Avg (30-Day) 578
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 13,459
  • Open Int (30-Day) 12,848
  • Expected Range 18.75 to 25.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.87
  • Number of Estimates 6
  • High Estimate -0.08
  • Low Estimate -1.21
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +29.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.97 +1.68%
on 03/27/26
28.96 -22.86%
on 03/02/26
-6.12 (-21.50%)
since 02/27/26
3-Month
21.97 +1.68%
on 03/27/26
36.44 -38.69%
on 01/12/26
-5.64 (-20.16%)
since 12/26/25
52-Week
13.52 +65.18%
on 04/07/25
36.44 -38.69%
on 01/12/26
+0.13 (+0.59%)
since 03/28/25

Most Recent Stories

More News
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...

BEAM : 22.14 (-0.23%)
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and...

BEAM : 22.14 (-0.23%)
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated...

BEAM : 22.14 (-0.23%)
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 22.14 (-0.23%)
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 34.23 (-0.58%)
ARKX : 28.24 (-2.39%)
NFLX : 93.52 (+0.10%)
META : 536.95 (+2.14%)
ROKU : 88.93 (+2.04%)
TXG : 19.66 (+0.92%)
GTLB : 21.28 (+4.57%)
AVGO : 293.72 (-2.31%)
TWST : 44.00 (-1.19%)
ILMN : 121.90 (+3.59%)
CRCL : 92.25 (-1.51%)
WRD : 7.05 (+1.44%)
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application...

BEAM : 22.14 (-0.23%)
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 22.14 (-0.23%)
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

BEAM : 22.14 (-0.23%)
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 22.14 (-0.23%)
2 Stocks to Buy Now to Profit from the Rise of Robotics

Investors betting on the future of automation in high-tech manufacturing would do well to keep these two stocks on their radar.

BEAM : 22.14 (-0.23%)
LCID : 9.41 (+0.11%)
ROK : 350.26 (-0.35%)
BA : 190.89 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 25.15
2nd Resistance Point 24.47
1st Resistance Point 23.33
Last Price 22.14
1st Support Level 21.51
2nd Support Level 20.83
3rd Support Level 19.69

See More

52-Week High 36.44
Fibonacci 61.8% 27.69
Fibonacci 50% 24.98
Fibonacci 38.2% 22.28
Last Price 22.14
52-Week Low 13.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.